The long non‑coding (lnc) RNA B‑Raf proto‑oncogene, serine/threonine kinase‑activated
non‑protein coding RNA (BANCR) is a well‑characterized oncogene, while its potential …

Context: There are several genetic and molecular evidences suggesting dysregulation of the
mammalian target of rapamycin (mTOR) pathway in thyroid neoplasia. Activation of the …

Long non-coding RNAs (lncRNAs) can serve as oncogenes and tumor suppressors and are
involved in tumorigenesis and chemotherapy resistance. Brain cytoplasmic RNA 1 …

Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to
difficulties in diagnosis and treatment. New molecular targets and better molecular profiles …

Recent advances in next-generation sequencing have revealed a variety of long noncoding
RNAs (lncRNAs). However, studies of lncRNAs are at a very early stage, our knowledge of …

Somatic mutations in BRAF, especially BRAFV600E, are frequently identified in papillary
thyroid cancer (PTC) tumors. It has been established that expression levels of numbers of …

Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

Long intergenic non‐coding RNA 152 (LINC00152) was reported to be tightly linked to
tumorigenesis and progression in multiple cancers. However, its biological role and …

Long-noncoding RNAs (lncRNAs) have been shown to participate in oncogenesis across a
variety of cancers and may represent novel therapeutic targets. However, little is known …

Objectives Cancer susceptibility candidate 2 (CASC2) and long noncoding RNA (lncRNA)
have been identified as a tumor suppressor in colorectal, lung, renal, and stomach cancer as …